Adequately defining tumor cell proportion in tissue samples for molecular testing improves interobserver reproducibility of its assessment

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine · 2004 · 11.5K citations

Medicine, Oncology, Pharmacology +16

<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations

Medicine, Molecular Genetics, Oncology +17

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

William Pao, Vincent A. Miller, Maureen F. Zakowski et al. · Proceedings of the National Academy of Sciences · 2004 · 4.3K citations · Full text

Medicine, Molecular Genetics, Oncology +16

The estimation of tumor cell percentage for molecular testing by pathologists is not accurate

Alexander J. Smits, J. Alain Kummer, Peter C. de Bruin et al. · Modern Pathology · 2013 · 213 citations · Full text

Medicine, Oncology, Pathology +12

A Prospective, Multi-Institutional Diagnostic Trial to Determine Pathologist Accuracy in Estimation of Percentage of Malignant Cells

Hollis Viray, Kevin Li, Thomas A. Long et al. · Archives of Pathology & Laboratory Medicine · 2013 · 106 citations

Medicine, Oncology, Pathology +9